Sabin-IPV

OPV is still the vaccine of choice for eradiation of wild poliomyelitis. However, after global polio eradication there will be no longer a necessity to tolerate Vaccine-Associated Paralytic Poliomyelitis (VAPP) as a consequence of vaccination with OPV. It’s clear that the demand for IPV will increase especially after OPV cessation.
After eradication of poliomyelitis access to live polioviruses will be highly restricted. The use of the attenuated Sabin virus instead of the wild polio strains is preferred; the risks associated with containment failures are less for Sabin-IPV.